BOSTON , Dec. 9, 2025 /PRNewswire/ --Â Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health...
BOSTON , Dec. 5, 2025 /PRNewswire/ --Â Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National...
CAMBRIDGE, Mass. , Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it...
BOSTON , Nov. 18, 2025 /PRNewswire/ --Â Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year...
Ginkgo provides an update on its third quarter financial results
Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure
BOSTON , Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development...
Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue- specific, and highly potent in vivo CAR therapies for autoimmune diseases
Ginkgo to Run AbDev AI Competition